RIBOLIFE-B (06938) announced the appointment of Dr. Anders Gabrielsen as Chief Medical Officer. Dr. Gabrielsen will oversee the company's overall clinical development, medical affairs, and regulatory compliance. Separately, Dr. John Taylor has been appointed Chief Business Officer, responsible for the company's business development, licensing activities, and strategic investments. Dr. Gan Liming has stepped down from the role of Chief Medical Officer but will continue to serve as an Executive Director, Co-CEO, and President of Global R&D. All changes are effective March 25, 2026.